Professor | Hongliang Li | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Hongliang Li
Contact Information	lihl@whu.edu.cn
Language ability	English, Chinese
Province	Hubei

Upload Avatar (500 x 500)

Name

Hongliang Li

Contact Information

lihl@whu.edu.cn

Language ability

English, Chinese

Province

Hubei

University/Lab Affiliation and Title	Wuhan University
Faculty	Medical School
Academic Background & Achievements	1994-1999 Bachelor of Clinical Medicine, Guangdong Medical College 1999-2002 Master of Pharmacology, Jinan University 2002-2005 PhD in Biochemistry and Molecular Biology, Peking Union Medical College Received 6 National Natural Science Foundation of China grants Published over 200 international journal articles
Work Experience	2005.07-2006.02 Postdoctoral Researcher, Peking Union Medical College 2006.02-2006.11 Postdoctoral Researcher, Harvard Medical School 2006.11-2008.11 Postdoctoral Researcher, University of Toronto 2008.11-present Professor, First Clinical College of Wuhan University 2009-present Director, Hubei Provincial Model Animal Research Center 2013-2020 Director, Model Animal Research Center of Wuhan University 2015-2020 Director, Animal Experiment Center/ABSL- III Laboratory of Wuhan University 2016-2020 Director, Model Animal Research Institute of Wuhan University 2017-2020 Dean, Basic Medical College of Wuhan University
Awards	2016 Hubei Province Science and Technology Progress First Prize: Development and Application of Gene Engineered Mouse Models of Cardio-Cerebrovascular Metabolic Diseases 2013 Hubei Province Science and Technology Progress First Prize: Pathogenesis and Clinical Prevention of Myocardial Remodeling 2011 National Science and Technology Progress Second Prize: Structural and Neural Remodeling Basis of Arrhythmia and its Clinical Prevention

University/Lab Affiliation and Title

Wuhan University

Faculty

Medical School

Academic Background & Achievements

1994-1999 Bachelor of Clinical Medicine, Guangdong Medical College
1999-2002 Master of Pharmacology, Jinan University
2002-2005 PhD in Biochemistry and Molecular Biology, Peking Union Medical College
Received 6 National Natural Science Foundation of China grants
Published over 200 international journal articles

Work Experience

2005.07-2006.02 Postdoctoral Researcher, Peking Union Medical College
2006.02-2006.11 Postdoctoral Researcher, Harvard Medical School
2006.11-2008.11 Postdoctoral Researcher, University of Toronto
2008.11-present Professor, First Clinical College of Wuhan University
2009-present Director, Hubei Provincial Model Animal Research Center
2013-2020 Director, Model Animal Research Center of Wuhan University
2015-2020 Director, Animal Experiment Center/ABSL- III Laboratory of Wuhan University
2016-2020 Director, Model Animal Research Institute of Wuhan University
2017-2020 Dean, Basic Medical College of Wuhan University

Awards

2016 Hubei Province Science and Technology Progress First Prize: Development and Application of Gene Engineered Mouse Models of Cardio-Cerebrovascular Metabolic Diseases
2013 Hubei Province Science and Technology Progress First Prize: Pathogenesis and Clinical Prevention of Myocardial Remodeling
2011 National Science and Technology Progress Second Prize: Structural and Neural Remodeling Basis of Arrhythmia and its Clinical Prevention

Areas of Focus	Cardiometabolic disease mechanisms and prevention Development of gene knockout and transgenic animal models
Publications	The E3 Ligase TRIM16 Is a Key Suppressor of Pathological Cardiac Hypertrophy, Li H et al., 2022 N-acetylgalactosaminyltransferase-4 protects against hepatic ischemia/reperfusion injury by blocking apoptosis signal-regulating kinase 1 N-terminal dimerization, Li H et al., 2022 Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia, Li H et al., 2021 Pharmacological inhibition of arachidonate 12-lipoxygenase ameliorates myocardial ischemia-reperfusion injury in multiple species, Li H et al., 2021 TMBIM1 is an inhibitor of adipogenesis and its depletion promotes adipocyte hyperplasia and improves obesity-related metabolic disease, Li H et al., 2021 A kinome screen reveals that Nemo-like kinase is a key suppressor of hepatic gluconeogenesis, Li H et al., 2021 The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19, Li H et al., 2021 Global Burden of Disease Study 2019 suggests that metabolic risk factors are the leading drivers of the burden of ischemic heart disease, Li H et al., 2021 In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19, Li H et al., 2020 Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis, Li H et al., 2020 Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes, Li H et al., 2020 Longitudinal association between markers of liver injury and mortality in COVID-19 in China, Li H et al., 2020 Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19, Li H et al., 2020 Unexpected Rapid Increase in the Burden of Nonalcoholic Fatty Liver Disease in China From 2008 to 2018: A Systematic Review and Meta-Analysis, Li H et al., 2019 Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases, Li H et al., 2019 An ALOX12–12-HETE–GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury, Li H et al. The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis, Li H et al., 2018 Restoration of Circulating MFGE8 (Milk Fat Globule-EGF Factor 8) Attenuates Cardiac Hypertrophy Through Inhibition of Akt Pathway, Li H et al., 2017 Insights into innate immune signaling in controlling cardiac remodeling, Li H et al., 2017 A long non-coding RNA defines an epigenetic check point for cardiac hypertrophy, Li H et al., 2016

Areas of Focus

Cardiometabolic disease mechanisms and prevention
Development of gene knockout and transgenic animal models

Publications

The E3 Ligase TRIM16 Is a Key Suppressor of Pathological Cardiac Hypertrophy, Li H et al., 2022
N-acetylgalactosaminyltransferase-4 protects against hepatic ischemia/reperfusion injury by blocking apoptosis signal-regulating kinase 1 N-terminal dimerization, Li H et al., 2022
Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia, Li H et al., 2021
Pharmacological inhibition of arachidonate 12-lipoxygenase ameliorates myocardial ischemia-reperfusion injury in multiple species, Li H et al., 2021
TMBIM1 is an inhibitor of adipogenesis and its depletion promotes adipocyte hyperplasia and improves obesity-related metabolic disease, Li H et al., 2021
A kinome screen reveals that Nemo-like kinase is a key suppressor of hepatic gluconeogenesis, Li H et al., 2021
The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19, Li H et al., 2021
Global Burden of Disease Study 2019 suggests that metabolic risk factors are the leading drivers of the burden of ischemic heart disease, Li H et al., 2021
In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19, Li H et al., 2020
Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis, Li H et al., 2020
Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes, Li H et al., 2020
Longitudinal association between markers of liver injury and mortality in COVID-19 in China, Li H et al., 2020
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19, Li H et al., 2020
Unexpected Rapid Increase in the Burden of Nonalcoholic Fatty Liver Disease in China From 2008 to 2018: A Systematic Review and Meta-Analysis, Li H et al., 2019
Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases, Li H et al., 2019
An ALOX12–12-HETE–GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury, Li H et al.
The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis, Li H et al., 2018
Restoration of Circulating MFGE8 (Milk Fat Globule-EGF Factor 8) Attenuates Cardiac Hypertrophy Through Inhibition of Akt Pathway, Li H et al., 2017
Insights into innate immune signaling in controlling cardiac remodeling, Li H et al., 2017
A long non-coding RNA defines an epigenetic check point for cardiac hypertrophy, Li H et al., 2016

Cardiometabolic Disease Mechanisms Prevention Gene Knockout Transgenic Animal Models Development

Zhigang She - Wuhan University

Zhuo Wang - Southern University of Science and Technology

Ruilin Zhang - Wuhan University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us